Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan

被引:0
作者
Shetty, SS [1 ]
Delgrande, D [1 ]
机构
[1] Novartis Inst Biomed Res, Summit, NJ 07901 USA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of valsartan and other nonpeptide angiotensin II type 1 (AT(1)) receptor blockers on the prejunctional actions of angiotensin II were investigated in the isolated left atria of rat. Norepinephrine stores in rat atria were loaded with [H-3] norepinephrine, and neuronal norepinephrine release was deduced from the radioactivity efflux. Angiotensin II (10(-9) to 10(-6) M) produced concentration-dependent enhancement of the electrical stimulation-induced efflux of [H-3] norepinephrine from the preparation. Pretreatment of tissues with valsartan, irbesartan, eprosartan, or losartan (10(-8) to 10(-6) M) produced concentration- dependent inhibitions of the stimulation-induced efflux of radioactivity observed in the presence of angiotensin II (10(-7) M). The AT(1) receptor blockers did not decrease the "basal" stimulation-induced overflow of radioactivity but rather selectively inhibited the angiotensin II-mediated augmentation of the response. Regression analyses of the inhibition of the angiotensin II-mediated response by valsartan, irbesartan, eprosartan, and losartan revealed corresponding log IC50 values (log M, with 95% confidence intervals) of -7.78 (-8.19, -7.51), -7.65 (-8.02, -7.40), -7.12 (-7.37, -6.86), and -6.75 (-7.00, -6.40), indicating that the IC50 values for valsartan and irbesartan are significantly lower than those for eprosartan and losartan. Thus, valsartan is a potent inhibitor of the prejunctional facilitatory effect of angiotensin II on the release of norepinephrine from peripheral sympathetic nerves. This implies that the therapeutic domain of valsartan may be extended to include pathophysiological conditions such as congestive heart failure wherein prejunctional angiotensin II receptors apparently play a significant role. Whether the high potency of valsartan translates into a significant clinical advantage relative to the other agents tested remains to be ascertained.
引用
收藏
页码:179 / 186
页数:8
相关论文
共 40 条
  • [11] Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist
    Criscione, L
    Bradley, WA
    Buhlmayer, P
    Whitebread, S
    Glazer, R
    Lloyd, P
    Mueller, P
    deGasparo, M
    [J]. CARDIOVASCULAR DRUG REVIEWS, 1995, 13 (03): : 230 - 250
  • [12] Effects of chronic treatment with losartan and enalaprilat on [H-3]-norepinephrine release from isolated atria of Wistar-Kyoto and spontaneously hypertensive rats
    Foucart, S
    Patrick, SK
    Oster, L
    deChamplain, J
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (01) : 61 - 69
  • [13] THE RELATIONSHIP OF THE SYMPATHETIC NERVOUS-SYSTEM AND THE RENIN-ANGIOTENSIN SYSTEM IN CONGESTIVE HEART-FAILURE
    FRANCIS, GS
    [J]. AMERICAN HEART JOURNAL, 1989, 118 (03) : 642 - 648
  • [14] FRANCO R, 1976, ARCH INT PHARMACOD T, V224, P55
  • [15] HETERORECEPTOR-MEDIATED MODULATION OF NORADRENALINE AND ACETYLCHOLINE-RELEASE FROM PERIPHERAL-NERVES
    FUDER, H
    MUSCHOLL, E
    [J]. REVIEWS OF PHYSIOLOGY BIOCHEMISTRY AND PHARMACOLOGY, VOL 126, 1995, 126 : 265 - 412
  • [16] Grieve A.P., 1996, STAT TOXICOLOGY, P87
  • [17] Different receptors for angiotensin II at pre- and postjunctional level of the canine mesenteric and pulmonary arteries
    Guimaräes, S
    Paiva, MQ
    Moura, D
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1998, 124 (06) : 1207 - 1212
  • [18] SYMPATHETIC-NERVE ACTIVITY - ROLE IN REGULATION OF BLOOD-PRESSURE IN SPONTANEOUSLY HYPERTENSIVE RAT
    JUDY, WV
    WATANABE, AM
    HENRY, DP
    BESCH, HR
    MURPHY, WR
    HOCKEL, GM
    [J]. CIRCULATION RESEARCH, 1976, 38 (06) : 21 - 29
  • [19] LEIER CV, 1990, CIRCULATION, V82, P68
  • [20] Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans
    Lo, MW
    Goldberg, MR
    McCrea, JB
    Lu, H
    Furtek, CI
    Bjornsson, TD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (06) : 641 - 649